$7.57
5.38% day before yesterday
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US48669G1058
Symbol
KZIA

Kazia Therapeutics Ltd Sponsored ADR Target price 2025 - Analyst rating & recommendation

Kazia Therapeutics Ltd Sponsored ADR Classifications & Recommendation:

Buy
88%
Hold
13%

Kazia Therapeutics Ltd Sponsored ADR Price Target

Target Price $19.38
Price $7.57
Potential
Number of Estimates 4
4 Analysts have issued a price target Kazia Therapeutics Ltd Sponsored ADR 2026 . The average Kazia Therapeutics Ltd Sponsored ADR target price is $19.38. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Kazia Therapeutics Ltd Sponsored ADR to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Kazia Therapeutics Ltd Sponsored ADR stock has an average upside potential 2026 of . Most analysts recommend the Kazia Therapeutics Ltd Sponsored ADR stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Revenue Million $ 0.08 0.03
94.87% 57.13%
Net Margin -17,387.50% -1,902,137.00%
1,407.75% 10,839.68%

4 Analysts have issued a sales forecast Kazia Therapeutics Ltd Sponsored ADR 2026 . The average Kazia Therapeutics Ltd Sponsored ADR sales estimate is

$34.3k
Unlock
. This is
57.13% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$70.5k 11.88%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $80.0k 94.87%
2026
$34.3k 57.13%
Unlock
2027
$20.9k 39.07%
Unlock
2028
$669k 3,100.96%
Unlock
2029
$21.9m 3,180.51%
Unlock
2030
$116m 427.35%
Unlock
2031
$239m 106.89%
Unlock
2032
$365m 52.43%
Unlock

4 Kazia Therapeutics Ltd Sponsored ADR Analysts have issued a net profit forecast 2026. The average Kazia Therapeutics Ltd Sponsored ADR net profit estimate is

$-652m
Unlock
. This is
4,584.47% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-571m 4,004.10%
Unlock
, the lowest is
$-719m 5,071.10%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-13.9m 22.68%
2026
$-652m 4,584.47%
Unlock
2027
$-308m 52.77%
Unlock
2028
$-291m 5.40%
Unlock
2029
$780k 100.27%
Unlock
2030
$48.2m 6,078.21%
Unlock
2031
$98.7m 104.84%
Unlock
2032
$155m 56.91%
Unlock

Net Margin

2025 -17,387.50% 1,407.75%
2026
-1,902,137.00% 10,839.68%
Unlock
2027
-1,472,879.02% 22.57%
Unlock
2028
-43,517.20% 97.05%
Unlock
2029
3.54% 100.01%
Unlock
2030
41.64% 1,076.27%
Unlock
2031
41.22% 1.01%
Unlock
2032
42.44% 2.96%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Earnings Per Share $ -0.03 -0.81
91.18% 2,600.00%
P/E negative
EV/Sales 374.23

4 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast for earnings per share. The average Kazia Therapeutics Ltd Sponsored ADR EPS is

$-0.81
Unlock
. This is
3,950.00% lower
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.71 3,450.00%
Unlock
, the lowest is
$-0.89 4,350.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.03 91.18%
2026
$-0.81 2,600.00%
Unlock
2027
$-0.38 53.09%
Unlock
2028
$-0.36 5.26%
Unlock
2029
$0.00 100.00%
Unlock
2031
$0.12 100.00%
Unlock
2032
$0.19 58.33%
Unlock

P/E ratio

Current -378.50 651.99%
2026
-9.40 97.52%
Unlock
2027
-19.91 111.81%
Unlock
2028
-21.05 5.73%
Unlock
2029
7,892.05 37,591.92%
Unlock
2030
127.14 98.39%
Unlock
2031
62.07 51.18%
Unlock
2032
39.56 36.27%
Unlock

Based on analysts' sales estimates for 2026, the Kazia Therapeutics Ltd Sponsored ADR stock is valued at an EV/Sales of

374.23
Unlock
and an P/S ratio of
389.99
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 160.31 1,341.64%
2026
374.23 133.44%
Unlock
2027
613.49 63.93%
Unlock
2028
19.16 96.88%
Unlock
2029
0.58 96.95%
Unlock
2030
0.11 81.03%
Unlock
2031
0.05 51.71%
Unlock
2032
0.04 34.39%
Unlock

P/S ratio

Current 167.06 1,805.31%
2026
389.99 133.45%
Unlock
2027
639.34 63.93%
Unlock
2028
19.97 96.88%
Unlock
2029
0.61 96.95%
Unlock
2030
0.12 81.04%
Unlock
2031
0.06 51.65%
Unlock
2032
0.04 34.41%
Unlock

Current Kazia Therapeutics Ltd Sponsored ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Dec 12 2025
Maxim Group
Locked
Locked
Locked Oct 02 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 10 2025
Maxim Group
Locked
Locked
Locked Jun 11 2025
Maxim Group
Locked
Locked
Locked Feb 06 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 12 2025
Locked
Maxim Group:
Locked
Locked
Oct 02 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 10 2025
Locked
Maxim Group:
Locked
Locked
Jun 11 2025
Locked
Maxim Group:
Locked
Locked
Feb 06 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today